The pupose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Condition:- Acromegaly Study Type: InterventionalStudy Design: Treatment Eligibility Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria:Diagnosis of acromegaly IGF-I levels >=1.3xULN (upper limit of normal) at screening No history of radiotherapy or prior treatment with other drugs for acromegaly Minimum of two months must have elapsed post surgery prior to screening Exclusion Criteria:Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations AST/ALT >= 3xULN (upper limit of normal) Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI Visual field defects (except post surgical stable residual defects) Unable to self administer drug Contact Details:Australia, New South WalesResearch Center, Darlinghurst, New South Wales, 2010, Australia; Recruiting Australia, VictoriaResearch Center, Fitzroy, Victoria, 3065, Australia; Recruiting

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.